ReviewBMC neurology2025
Acute and reversible dyskinesias secondary to lithium toxicity: case report and literature review.
Review in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An update on trismus: etiology, diagnosis and treatment.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLithium can cause several neurological side effects, including altered consciousness, delirium, cerebellar symptoms, parkinsonism, and seizures. Also, dyskinesias can be a possible manifestation of lithium intoxication. The clinical picture of dyskinesias secondary to lithium intoxication is still unclear. CASE PRESENTATION: We here describe the case of a 75-year-old woman who developed acute and reversible dyskinesia manifesting as generalised chorea because of lithium intoxication. The patient had a medical history of bipolar disorder type 2 and at least 20 years of continuous lithium monotherapy (150 mg, 1 tablet 3 times/day). Dyskinesias were associated with a high serum lithium level of 2.15 mEq/L. Imaging and EEG showed no relevant abnormalities. On the sixth day after admission, dyskinesias faded away when the lithium serum level decreased to 0.4 mmol/L. When critically reviewing the existing literature, we found a total of 33 cases, with an average age of 59.7 years, predominantly female. In these cases, the average lithium peak at the onset of dyskinesia was 2.25 mEq/L, with symptoms typically appearing 4.2 days after reaching peak lithium levels. DISCUSSION: Lithium toxicity, even at therapeutic serum concentrations, may induce abrupt-onset dyskinesia in susceptible individuals, likely mediated by reversible functional disturbances within the basal ganglia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.